UCLA and Children’s Hospital Los Angeles (CHLA) have secured a grant of up to $17.25 million from Aligning Research to Impact Autism (ARIA) to join the Innovative Medicine and Precision Approaches to Clinical Trials (IMPACT) Network. As one of 12 international sites, the newly formed IMPACT-LA partnership will focus on accelerating clinical trial readiness for autism and related neurodevelopmental conditions through large-scale data collection and research infrastructure.
Did You Know? The IMPACT-LA site will recruit and follow participants aged 0 to 18 years, marking a shift toward longitudinal data collection that incorporates standardized behavioral, genetic, and biomarker assessments.
Why this research partnership matters
The creation of the IMPACT-LA site addresses a significant gap in historical autism research, which has often favored verbal, higher-functioning populations. According to Dr. Rajsekar Rajaraman, an associate professor at the David Geffen School of Medicine at UCLA, the network provides the necessary structure to conduct more inclusive and rigorous clinical trials. By standardizing the collection of biospecimens and high-quality datasets, the initiative aims to build a scientific resource that supports the development of precise medical interventions.
Expert Insight: By serving as both a research site and a Clinical Coordinating Center (CCC), UCLA is positioning itself at the nexus of global autism research. The dual role allows the institution to influence the administrative standards of the network while simultaneously conducting on-the-ground clinical work, a rare combination that could significantly shorten the timeline between discovery and therapy.
What happens next for the IMPACT Network
The IMPACT-LA site will begin the multi-year process of gathering detailed clinical and biological data from participants. Families involved in the study will receive feedback throughout their participation, according to project documentation. Meanwhile, UCLA will continue its work as a Clinical Coordinating Center alongside Boston Children’s Hospital, providing the administrative oversight required to manage operations across all 12 global sites.
Frequently Asked Questions
What is the primary goal of the IMPACT-LA site?
The site aims to accelerate clinical trial readiness and implementation for autism and related neurodevelopmental conditions by combining clinical assessments, biological data, and open data sharing.
Who is leading the research efforts at the Los Angeles sites?
The project is led by co-Principal Investigators Dr. Rajsekar Rajaraman and Dr. Rujuta B. Wilson of the David Geffen School of Medicine at UCLA, working in partnership with Dr. Jonathan Santoro of CHLA.
How will this network differ from previous autism studies?
Unlike historical studies that often focused on verbal, higher-functioning individuals, this network intends to use a structured, inclusive approach to gather data on a broader range of patients, including those with profound autism.
How might these standardized, large-scale datasets change the way clinicians approach personalized autism therapies in the future?
Worth a look